title: [Association between RIPK4 relative copy number and prognosis of colorectal cancer patient after oxaliplatin-based chemotherapy].
abstract: OBJECTIVE
  To investigate the association between receptor-interacting kinase protein 4 (RIPK4) relative copy number (RCN) and prognosis of stage III( colorectal cancer (CRC) patients treated with oxaliplatin-based chemotherapy.
  
  
  METHODS
  RIPK4 RCN was determined by real-time PCR and then dichotomized into high RIPK4 RCN group(n=35) and low RIPK4 RCN group (n=104) using the third quartile as the cut-off point. Overall survival (OS) and recurrence-free survival (RFS) were compared between high and low RIPK4 RCN groups. The subgroup prognostic analysis was also conducted based on tumor site.
  
  
  RESULTS
  The median follow-up period was 49 months (ranged 4 to 98 months). Patients with high RIPK4 RCN had poorer OS than those with low RIPK4 RCN, which reached marginal significance(median OS, 43.0 months vs. 53.5 months, P=0.074). Meanwhile there was no significant difference of RFS between two groups (P=0.352). In colon cancer subgroup, high RIPK4 RCN was significantly associated with poor OS (median OS, 31.5 months vs. 56.6 months, P=0.015) but not with RFS (P=0.135). In rectal cancer subgroup, RIPK4 RCN was not associated with both OS and RFS (P=0.981, P=0.738). Multivariate analysis revealed that high RIPK4 RCN was an independent prognostic factor of OS in stage III( CRC patients treated with oxaliplatin-based chemotherapy (HR=2.903, 95% CI: 1.275 to 6.610).
  
  
  CONCLUSIONS
  RIPK4 RCN is significantly associated with OS in stage III( colon cancer patients receiving oxaliplatin-based chemotherapy and may be a novel biomarker that can predict the efficacy of oxaliplatin in colon cancer patients.
authors.affiliation: Department of Gastroenterology, The Shanghai Tenth People's Hospital, Tongji University, Shanghai 200072, China. liuzhanju88@126.com.
authors.forename: Kangsheng
authors.initials: K
authors.lastname: Peng
authors.forename: Moubin
authors.initials: M
authors.lastname: Lin
authors.forename: Qing
authors.initials: Q
authors.lastname: Wei
authors.forename: Huaguang
authors.initials: H
authors.lastname: Li
authors.forename: Chenbo
authors.initials: C
authors.lastname: Zhang
authors.forename: Ruting
authors.initials: R
authors.lastname: Xie
authors.forename: Zhanju
authors.initials: Z
authors.lastname: Liu
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics; D005472:Fluorouracil; D018628:Gene Dosage; D006801:Humans; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin / Q000008:administration & dosage; D011379:Prognosis; D017346:Protein Serine-Threonine Kinases / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; C417187:RIPK4 protein, human; D017346:Protein Serine-Threonine Kinases; D005472:Fluorouracil